English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Efficacy of standardized short ragweed sublingual immunotherapy tablet (SLIT-T), MK-3641 (Merck/ALK; 12 Amb a 1-U of Ambrosia artemisiifolia) treatment on Canadian ragweed-allergic subjects was assessed using subgroup analysis of data from 2 multinational, randomized, double-blind, placebo-controlled clinical trials designed to evaluate ragweed SLIT-T efficacy and safety in adults with ragweed pollen-induced allergic rhinitis with or without conjunctivitis (AR/C), with or without asthma.

allergy, asthma and clinical immunology/allergy, asthma, and clinical immunology

Efficacy and safety of standardized short ragweed sublingual immunotherapy tablet (SLIT-T) treatment in Canadian subjects with ragweed pollen-induced rhinitis with or without conjunctivitis